摘要
糖尿病下肢缺血是一种严重的糖尿病并发症,可导致下肢感染、溃疡和坏死,严重时甚至需要截肢。传统治疗和外科治疗在临床上亦有诸多局限性,随着以干细胞治疗为主的再生医学兴起,为糖尿病下肢缺血的治疗带来新的可能性。糖尿病下肢缺血的干细胞治疗中最引人瞩目的是间充质干细胞(MSC)。MSC是一类具有多向分化潜能且低免疫原性的细胞,通过向患者种植,可以改善患者下肢缺血症状、调节免疫,提升患者的生存质量。本文通过对不同组织来源的MSC治疗糖尿病下肢缺血研究进展及研究新方向进行总结,以期为该病的治疗提供理论依据,并对未来的研究寻找方向。
Diabetic lower limb ischemia is a serious diabetic complication that can lead to lower extremity infection,ulcers,necrosis and even amputation.Traditional and surgical treatment have many limitations,and stem cell therapy brings new possibilities for the treatment of diabetic lower limb ischemia.The most promising cells for lower limb ischemia in diabetes are mesenchymal stem cells(MSCs).MSCs are a kind of pluripotent stem cells with low immunogenicity and multidirectional differentiation ability.By transplantation,it can relieve lower limb ischemia,regulate immunity,and improve the quality of life in patients.This article reviews progress and new findings of research on the treatment of diabetic lower limb ischemia with MSCs derived from different tissues,provide a theoretical basis,and insight for future research.
作者
胡青林
黄平平
Hu Qinglin;Huang Pingping(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Hematological Diseases,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China)
出处
《中华细胞与干细胞杂志（电子版）》
2021年第4期246-250,共5页
Chinese Journal of Cell and Stem Cell（Electronic Edition）
基金
中国医学科学院医学与健康科技创新工程项目(2017-I2M-1-016)。
关键词
间充质干细胞
糖尿病下肢缺血
进展
Mesenchymal stem cells
Diabetic lower limb ischemia
Progress
